KELOWNA, BC / ACCESSWIRE / November 2, 2023 / Tryp Therapeutics, Inc. ("Tryp" or the "Company") (CSE:TRYP), a clinical-stage biotechnology...
STOCKHOLM, SE / ACCESSWIRE / November 02, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical...
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 1, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release...
NEWARK, CA / ACCESSWIRE / November 1, 2023 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced the achievement...
Management representatives from 1,428 provider organizations are electing to deflect mounting solution delivery concerns to outsourcing vendors, according to 91%...
VANCOUVER, BC / ACCESSWIRE / November 1, 2023 / Lotus Ventures Inc. (CSE:J)(OTC:LTTSF) ("Lotus" or the "Company") a B.C. based...
BEVERLY HILLS, CA / ACCESSWIRE / November 1, 2023 / Dr. David Amron, board-certified dermatologic surgeon and renowned Lipedema specialist,...
Planegg/Martinsried, November 4, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the...
Analysis of week 36 data from Phase 2b ORIGIN study shows atacicept 150 mg substantially reduces serum Gd-IgA1 and resolves...
The first experimental agent from the enLIGHTEN™ Discovery Platform is Alpha-201-macro1, an investigational viral immunotherapy designed to activate innate immune...
Data further characterize the mechanism for Gamida Cell’s proprietary nicotinamide (NAM) technology’s expansion and enhancement of cellsBOSTON, Nov. 04, 2023...
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patientsWOBURN, Mass.,...
Allschwil, Switzerland – November 3, 2023 Idorsia Ltd (SIX: IDIA) announced today that further data for aprocitentan, Idorsia’s investigational dual...
MIAMI, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”) a special purpose...
In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic cancer...